Oramed Pharmaceuticals Announces Publication in the Journal of Diabetes Science and Technology

Results Describe Preclinical Trials Demonstrating Retained GLP-1 Analog Activity When Delivered With Oramed’s Oral Drug Delivery Formulations
JERUSALEM, December 1, 2010 /PRNewswire via COMTEX/ —

Oramed
Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( http://chinese.oramed.com), a developer
of oral drug delivery solutions, announces a publication in the Journal of
Diabetes Science and Technology’s […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD

JERUSALEM, November 15, 2010 /PRNewswire via COMTEX/ –Oramed
Pharmaceuticals Inc. (OTCBB: ORMP) (http://chinese.oramed.com), a developer of
oral drug delivery systems, presented the results of its recently completed
Phase IIb trial. The multicenter, placebo-controlled, randomized,
double-blind study conducted in 29 patients with Type II diabetes assessed
the safety of ORMD-0801 in […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals to Present Results of an Oral Insulin Administration Study at the Tenth Annual Meeting of the Diabetes Technology Society (November 11-13, 2010; Bethesda, MD)

JERUSALEM, October 26, 2010 /PRNewswire via COMTEX/ –Oramed
Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://chinese.oramed.com), a developer of
oral drug delivery systems, announced today that its work entitled “Extended
exposure to an oral insulin formulation yields decreased insulin secretion in
Type II diabetes subjects,” will be presented at the Tenth Annual […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Oramed’s Oral Insulin Capsules

JERUSALEM, Israel, July 7, 2010 /PRNewswire via COMTEX/ –Oramed
Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://chinese.oramed.com), a developer of
oral delivery systems, today announced that Oramed entered into a
Manufacturing Supply Agreement (MSA) with sanofi-aventis. According to the
MSA, sanofi-aventis will supply Oramed with specified quantities of
recombinant human insulin to be […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association

JERUSALEM, June 28, 2010 /PRNewswire via COMTEX/ –Results of First Exposure of Type I Diabetes Patients to Oramed’s Oral
Insulin and of a First-in-Humans Study With its Oral GLP-1 Analog

Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) announced today that its
executive management is participating in the 2010 Scientific Sessions […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010

JERUSALEM, June 15, 2010 /PRNewswire via COMTEX/ –Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP) (http://chinese.oramed.com), a developer of
alternative drug delivery systems, announced today that results of two of its
clinical trials will be presented by Chief Scientific Officer Dr. Miriam
Kidron, at the forthcoming 70th Annual Scientific Sessions of the […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals to Present at the 9th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2010

Oramed to Present on Wednesday, June 16th at 11:50 a.m. (IDT)

JERUSALEM, June 8, 2010 /PRNewswire via COMTEX/ –Oramed Pharmaceuticals
Inc. (OTCBB: ORMP.OB), (http://chinese.oramed.com), a developer of oral delivery
systems, today announced today that it was chosen to present at the 9th
National Life Science & Technology Week ILSI-BIOMED […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals Forms Joint Venture – Launches Entera Bio Ltd.

JERUSALEM, June 2, 2010 /PRNewswire via COMTEX/ –Oramed Pharmaceuticals
Inc. (OTCBB: ORMP), a developer of oral drug delivery systems, announced
today that its subsidiary Oramed Ltd. entered into a joint venture agreement
with Laser Detect Systems Ltd. (“Laser Detect”), an Israeli company listed on
the Tel Aviv Stock Exchange, […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism

JERUSALEM, May 26, 2010 /PRNewswire via COMTEX/ –Study Data Shows ORMD-0801 Resulted in Glucose and C-Peptide Reduction

Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://chinese.oramed.com), a
developer of alternative drug delivery systems, announced today that the
paper entitled, “Open-label study to assess the safety and pharmacodynamics
of five oral insulin formulations […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors

JERUSALEM, May 18, 2010 /PRNewswire via COMTEX/ –Oramed Pharmaceuticals
Inc. (OTCBB: ORMP.OB) announced that Dr. Michael Berelowitz, MD, joins Oramed
Pharmaceuticals’ Board of Directors. Dr. Berelowitz is currently Senior Vice
President and Head of Clinical Development and Medical Affairs in the
Specialty Care Business Unit at Pfizer, Inc., the […]

Categories: 新闻通稿|Tags: |